Description

The global in vitro diagnostics market in terms of revenue is set to grow by US$ 27 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.4% during the forecast period, according to data and analytics company StrategyHelix. Growth in the geriatric population, increasing prevalence of chronic and infectious diseases, rising demand for in-vitro diagnostics during COVID-19 pandemic are the key factors driving market growth.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for in vitro diagnostics. The global in vitro diagnostics market is segmented on the basis of product, technique, application, region, and end user. By product, it is categorized into instruments, reagents, and software & services. The reagents segment held the largest market share in 2020. By technique, the in vitro diagnostics market is divided into immunodiagnostics, poc testing, molecular diagnostics, hematology, tissue diagnostics, and clinical chemistry. In 2020, the immunodiagnostics segment held the largest share of the market, and the molecular diagnostics segment is anticipated to register the highest CAGR during 2021 to 2027. Based on application, the in vitro diagnostics market is divided into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. In vitro diagnostics market by region is divided into North America, Asia Pacific, Europe, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as Abbott Laboratories, Alere Inc., Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, Biomerieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd, Ortho-Clinical Diagnostics Inc. (Carlyle Group), Panasonic Healthcare Holdings Co. Ltd. (Bayer AG), QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., Werfen Group.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the in vitro diagnostics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: instruments, reagents, and software & services
Technique: immunodiagnostics, poc testing, molecular diagnostics, hematology, tissue diagnostics, and clinical chemistry
Application: infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others
End user: hospitals, laboratories, homecare, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the global in vitro diagnostics market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global in vitro diagnostics market looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. In Vitro Diagnostics Market by Product
4.1 Instruments
4.2 Reagents
4.3 Software & Services
5. In Vitro Diagnostics Market by Technique
5.1 Immunodiagnostics
5.2 Poc Testing
5.3 Molecular Diagnostics
5.4 Hematology
5.5 Tissue Diagnostics
5.6 Clinical Chemistry
6. In Vitro Diagnostics Market by Application
6.1 Infectious Diseases
6.2 Cancer
6.3 Cardiac Diseases
6.4 Immune System Disorders
6.5 Nephrological Diseases
6.6 Gastrointestinal Diseases
6.7 Others
7. In Vitro Diagnostics Market by Region
7.1 North America
7.2 Asia Pacific
7.3 Europe
7.4 Rest Of The World (Row)
8. In Vitro Diagnostics Market by End User
8.1 Hospitals
8.2 Laboratories
8.3 Homecare
8.4 Others
9. Company Profiles
9.1 Abbott Laboratories
9.2 Alere Inc.
9.3 Beckman Coulter Inc. (Danaher Corporation)
9.4 Becton, Dickinson and Company
9.5 Biomerieux SA
9.6 Bio-Rad Laboratories, Inc.
9.7 F. Hoffmann-La Roche Ltd
9.8 Ortho-Clinical Diagnostics, Inc. (Carlyle Group)
9.9 Panasonic Healthcare Holdings Co., Ltd. (Bayer AG)
9.10 QIAGEN N.V.
9.11 Siemens Healthineers AG
9.12 Sysmex Corporation
9.13 Thermo Fisher Scientific Inc.
9.14 Werfen Group
10. Appendix
10.1 About StrategyHelix
10.2 Disclaimer